Literature DB >> 17492265

[Prospective study using a modified Montgomery-Asberg Depression Scale].

H-J Möller1, J Schnitker.   

Abstract

BACKGROUND: The Montgomery-Asberg Depression Scale (MADRS) is one of the most widely used scales in depression research today. Although relatively pragmatic in its present form, it still takes too long to complete when little time is available, e.g. in observational studies in outpatient settings. A shortened version of the MADRS (sv-MADRS) was therefore developed for use in such situations. The object of this study was to demonstrate indirectly that the sv-MADRS corresponds adequately with the standard MADRS. PATIENTS AND METHODS: In the context of an observational study, 11,790 depressive patients were treated with escitalopram. A total of 11,580 with documented sv-MADRS and severe disorder according to the Clinicians's Global Impression Scale (CGI) could be included in the analysis of baseline findings prior to treatment with escitalopram. A total of 10,910 completed the 8-week observational period.
RESULTS: At baseline the sv-MADRS shows high internal consistency, which corresponds well with the German version of the MADRS. Overall the cross-sectional variables and those of change and evaluation show high correlations between CGI and sv-MADRS.
CONCLUSION: Results of validity analyses of correlation with the CGI severity measure and with the factor structure of the original MADRS version are encouraging. Further evaluations are required to test comparability with the original version.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17492265     DOI: 10.1007/s00115-007-2278-0

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  11 in total

1.  Structural validity of MADRS during antidepressant treatment.

Authors:  A Galinowski; P Lehert
Journal:  Int Clin Psychopharmacol       Date:  1995-09       Impact factor: 1.659

2.  Factor analysis of the Montgomery-Asberg Depression Rating Scale.

Authors:  W E Craighead; D D Evans
Journal:  Depression       Date:  1996

3.  Factor analysis of the Montgomery Asberg Depression Rating Scale in 251 bipolar II and 306 unipolar depressed outpatients.

Authors:  F Benazzi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2001-10       Impact factor: 5.067

4.  Efficacy of escitalopram in patients with severe depression: a pooled analysis.

Authors:  P-M Llorca; J-M Azorin; N Despiegel; P Verpillat
Journal:  Int J Clin Pract       Date:  2005-03       Impact factor: 2.503

5.  Comparison of escitalopram and citalopram efficacy: A meta-analysis.

Authors:  Pascal Auquier; Stéphane Robitail; Pierre-Michel Llorca; Benoît Rive
Journal:  Int J Psychiatry Clin Pract       Date:  2003       Impact factor: 1.812

6.  The validity of the depression rating scales in discriminating between citalopram and placebo in depression recurrence in the maintenance therapy of elderly unipolar patients with major depression.

Authors:  J Bent-Hansen; M Lunde; R Klysner; M Andersen; P Tanghøj; K Solstad; P Bech
Journal:  Pharmacopsychiatry       Date:  2003-11       Impact factor: 5.788

7.  A new depression scale designed to be sensitive to change.

Authors:  S A Montgomery; M Asberg
Journal:  Br J Psychiatry       Date:  1979-04       Impact factor: 9.319

8.  A three-factor analytic model of the MADRS in geriatric depression.

Authors:  R D Parker; Elizabeth P Flint; Hayden B Bosworth; Carl F Pieper; David C Steffens
Journal:  Int J Geriatr Psychiatry       Date:  2003-01       Impact factor: 3.485

9.  Rating depression severity in the elderly physically ill patient: reliability and factor structure of the Hamilton and the Montgomery-Asberg Depression Rating Scales.

Authors:  M F Hammond
Journal:  Int J Geriatr Psychiatry       Date:  1998-04       Impact factor: 3.485

10.  Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany.

Authors:  H-J Möller; S Langer; M Schmauss
Journal:  Pharmacopsychiatry       Date:  2007-03       Impact factor: 5.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.